|

MAPS Phase 3 MDMA To Treat PTSD Trial Results: WOW [GREAT News For NUMI, MindMed, MYCO & Atai ]

ByPsychedelic Spotlight

MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.

Also, there were 0 cases of serious adverse side effects in the MDMA group.

So which companies will be the largest benefactors of these results?

Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently

2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.

3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.

4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.

5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.

Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Clinical trials :

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #NUMIStock

Similar Posts

  • Interview With Christi Myers

    Listen, Podcasts

    In this episode of the Psychedelic Spotlight Podcast, our Director of Content catches up with Christi Myers, founder and director of Flow Wellness. Christi discusses her career as a paramedic and how that translates into her work now, helping people heal traumas with ketamine therapy.

  • LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]

    Listen, Videos

    Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
    So make sure you stick around for both.

    Timecodes:
    0:00 – Intro
    3:30 – New Phase 1 Clinical Trial
    9:45 – Changes in Leadership
    13:19 – New MindMed Partnership
    20:30 – Conclusion

    So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?

    First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.

    Why combine these two substances?
    What diseases could it help alleviate?
    And what is the timeline for this project?

    Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.

    Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.

    Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.

    Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.

    Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
    We talked about all sorts of interesting topics and I had a great time.

    I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
    https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
    https://www.instagram.com/sena__maria/

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video from Pexels

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMEDF #MindmedStock

  • Interview with Sam Chapman, Executive Director of the Healing Advocacy Fund

    Listen, Podcasts

    This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.